All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

GD2 is a disialoganglioside found on the outer cell membrane and is believed to play a role in neuronal development, differentiation and repair \[[@pone.0236115.ref001]\]. Prenatal expression of GD2 is found principally on neural and mesenchymal stem cells, with postnatal expression limited to peripheral nerves, elements of the central nervous system, and skin melanocytes \[[@pone.0236115.ref002]\]. Importantly, many cancer cells including neuroblastoma express GD2 on their surface \[[@pone.0236115.ref003]\]. Until recently, approximately two-thirds of patients diagnosed with high risk neuroblastoma would succumb to the disease despite obtaining remission. The abundant expression of GD2 on neuroblastoma but limited expression on normal cells made it an attractive target for anti-GD2 immunotherapy. We have reported that anti-GD2 (dinutuximab) is efficacious in improving neuroblastoma patient survival when administered to patients in remission as well as in relapsed or refractory disease \[[@pone.0236115.ref004], [@pone.0236115.ref005]\]. However, late relapses that diminish overall survival do occur \[[@pone.0236115.ref006], [@pone.0236115.ref007]\]. Although an increase in dosage or number of cycles of dinutuximab could potentially reduce late relapses, this approach is hampered by an increase in dinutuximab-associated toxicities. In particular, whole body allodynia, which is severe pain perceived in response to light touch, is the major side effect of dinutuximab, limiting its expanded usage and dosage. To address this problem, co-administration of morphine or other narcotics is common. Despite such measures, some patients still experience severe pain that interferes with the activities of daily living or totally disabling pain \[[@pone.0236115.ref004]\]. Most toxicities can be reduced, in part, by increasing infusion duration while maintaining overall dosage \[[@pone.0236115.ref008]\]. However, allodynia remains the major and the dose-limiting toxicity even on this modified schedule.

High levels of polyamines and ornithine decarboxylase (ODC) activity, the rate limiting enzyme in polyamine biosynthesis, are found in many human cancers including neuroblastoma \[[@pone.0236115.ref009], [@pone.0236115.ref010]\]. Mammalian cells sequentially synthesize three polyamines from ornithine. The first product is putrescine, which is then converted into spermidine and spermine. Difluoromethylornithine (DFMO, eflornithine) is an inhibitor of ODC which reduces serum polyamine levels with minimal toxicity but has little stand-alone anti-cancer activity \[[@pone.0236115.ref011]\]. On the other hand, DFMO in combination with various anti-cancer agents with diverse mechanisms of action have shown promising results in clinical trials \[[@pone.0236115.ref012]--[@pone.0236115.ref015]\].

Polyamines have also been linked to the nociceptive pathway. Polyamines can induce neuronal sensitization as well as the development of allodynia and hyperalgesia \[[@pone.0236115.ref016]\]. Consistent with this, a reduction in polyamine levels significantly reduced inflammation-induced and neuropathic pain in animal models \[[@pone.0236115.ref017]\]. In other pre-clinical studies, rats fed a polyamine deficient diet (PDD) displayed significantly less oxaliplatin-induced pain behavior \[[@pone.0236115.ref018]\]. In prostate cancer patients, a PDD decreased patient-reported cancer-associated pain with no detrimental side effects \[[@pone.0236115.ref019]\]. These results suggest that decreasing polyamines can reduce both cancer associated pain as well as pain arising from other sources.

The observation that for a variety of cancers and iatrogenic pain states a reduction in polyamine levels may improve quality of life has led us to hypothesize that polyamine depletion might also be an effective anti-allodynia strategy for anti-GD2 immunotherapy. Thus, this study had two objectives 1) to test the hypothesis that DFMO would alleviate anti-GD2 induced allodynia and 2) to determine if there is an association between plasma levels of polyamines and magnitude of pain behavior. The first objective was considered to be of primary clinical importance. Using a rat model of pain behavior, oral DFMO significantly reduced the allodynia induced by an i.v. injection with 14G2a, the murine version of dinutuximab. Our results suggest that DFMO may be an effective agent for reducing anti-GD2-induced allodynia and may be an important adjunct to dinutuximab immunotherapy in addition to, but regardless of, any function as an anti-cancer therapy adjunct.

Methods {#sec006}
=======

Animals and experimental design {#sec007}
-------------------------------

Experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of California, San Diego. (Protocol Number: S12314). All animal research followed the ARRIVE guidelines ([S1 Appendix](#pone.0236115.s004){ref-type="supplementary-material"}). Sixty-six male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 200-250g were housed in pairs and kept on a 12-h light/dark cycle. Food and water were available *ad libitum*. Seven to ten days prior to the experiment, drinking water was replaced with an aqueous solution containing 0.25%, 0.5% or 1.0% DMFO or water alone. The DFMO solutions were visually identical to plain water. Animals were weighed after arrival and then again at the start of the experiment. Animals were qualitatively assessed for any ill effects of the DFMO on motor skills, reflexes and general health activity to look for possible DFMO behavioral side effects; none were observed.

For three days prior to the experiment, animals were acclimated to the behavioral testing room, equipment and procedures. On the day of the experiment, animals were placed in individual plastic test chambers with wire mesh floors to allow access to the hindpaws. Basal mechanical hindpaw withdrawal threshold (50% probability) was assessed by means of a set of calibrated von Frey filaments (Stoelting, Wood Dale, IL) with buckling forces between 0.41--15.1g. When the animal was quiet and resting on all four paws, a filament, beginning with the 2.0g filament, was pressed perpendicularly against the surface of the hindpaw until it bent slightly. A response consisted of either a brisk movement away from the probe (escape) or a paw lick. Pressure was maintained for 6s or until a response occurred. Successive stimuli were separated by 15 to 30 seconds. Stimuli were presented in ascending order of stiffness until a response occurred or the stiffest filament in the set was used, statistically these animals were treated as having a 15.1g response. If a response occurred, filaments of decreasing strength were applied until the animal no longer responded, at which point filaments were again presented in ascending order. This pattern was repeated for four stimuli presentations after the first withdrawal response, and the 50% probability withdrawal threshold determined \[[@pone.0236115.ref020]\]. Following baseline determination, rats were lightly anesthetized with 2% isoflurane and 0, 1 or 2 mg/kg of 142Ga in saline injected via the tail vein. Rats were immediately returned to the test chamber and thresholds re-determined at 0.5, 1, 2, 3, 4, 5, 8 and 24 h post injection. Rats were returned to their home cages for the periods after the 5 and 8 h time points to allow them access to food and fluids. All experiments began between 9 and 10 a.m. The person performing the behavioral testing was unaware of the contents of the fluid in the water bottles. At the end of experiments, the rats were deeply anesthetized with 5% isoflurane and blood withdrawn via cardiac puncture for polyamine and DFMO analysis before sacrifice by CO2 and bilateral pneumothorax in accordance with American Veterinary Medical Association (AVMA) Guidelines.

DFMO and anti-GD2 {#sec008}
-----------------

Murine anti-GD2 (14G2a) was manufactured by BioTechnetics Inc. San Diego CA and was from clinical stock originally used in Phase I trials for neuroblastoma \[[@pone.0236115.ref021]\]. The morning of the experiment it was diluted in physiological saline and administered at a dosage of 1 or 2 mg/kg. DFMO was synthesized by Genzyme Corporation (Lot \#PD39CF) and graciously provided by Professor Patrick M. Woster, Ph.D. from Medical University of South Carolina, Charleston, South Carolina. It was diluted in tap water on the day that it was first used and placed in the animals' water bottles at room temperature until the end of the experiment. Bottles were refilled as necessary.

Polyamine and DFMO measurement {#sec009}
------------------------------

If the first objective was met, our second objective was to determine the relationship with serum levels of polyamines, which are known to be reduced by oral DFMO, with magnitude of pain behavior. Serum was stored at -20°C before being batch sent for DFMO and polyamine analysis at the UCSD Biochemical Genetics and Metabolomics Laboratory (<http://ucsdbglab.org/metabolomics/Panels.asp>) using high performance liquid chromatography and mass spectrometry (LC-MS/MS). Briefly, 100μL of rat serum was vortex-mixed with 1mL of ice-cold methanol containing stable-isotope labeled internal standards (^2^H~8~-putrescine (d~8~-putrescine), ^2^H~20~-spermine (d~20~-spermine) and ^2^H~2~-ornithine, incubated for 30 minutes at -20°C and centrifuged at 17,136 x *g* at 5°C. Supernatants were evaporated to dryness and reconstituted in 50μL of 5% acetonitrile + 3.6mM ammonium formate+0.1% formic. Polyamines and DFMO were separated at room temperature on a 150 x 2.1mm (5μm particle size) TSKgel Amide-80 column at a flow rate of 0.3mL/min. Identities of polyamines and DFMO were validated by LC-MS/MS.

Because of the inability to reliably measure spermidine or spermine using our initial methodology, we developed a second method to measure polyamines adapted from \[[@pone.0236115.ref022]\] and \[[@pone.0236115.ref023]\]. Urethane derivatives di-isobutoxy- (^i^BuO) putrescine, tri- ^i^BuO-spermidine and tetra- ^i^BuO- spermine were analyzed using above described stable-isotope dilutions, with di- ^i^BuO-d~8~-putrescine and tetra-^i^BuO-d~20~-spermine internal standards. Briefly, rat serum was deproteinized with 4% trichloracetic acid, adjusted to pH 9 with ammonium hydroxide and ammonium formate buffer, and reacted with isobutyl chloroformate at 35°C. Carbamoyl derivatives were extracted by solid-phase extraction (SPE) on a 30mg Strata-X reversed phase cartridge conditioned with methanol and water, washed with 5% acetonitrile, eluted with 90% acetonitrile + 0.1% formic acid and dried. Eluate was then reconstituted in 50% acetonitrile + 0.1% formic acid and analyzed in gradient mode by LC-MS/MS on a Sciex API4000 MS coupled to an Agilent 1200 series LC on a Kinetex C18 LC column (100x2.1mm; 5μm).

Further details on polyamine analysis methodology and raw data on the figures presented in this manuscript are available as supplemental information ([S1](#pone.0236115.s002){ref-type="supplementary-material"} and [S2](#pone.0236115.s003){ref-type="supplementary-material"} Methods and [S1 Table](#pone.0236115.s001){ref-type="supplementary-material"} and [S1 Raw data](#pone.0236115.s005){ref-type="supplementary-material"}).

Statistics {#sec010}
----------

Sample size determination for allodynia experiments was determined at 80% power and a significance of 0.05 using the standard sample size calculations \[[@pone.0236115.ref024]\] and using the maximum values of allodynia determined for 1 mg/ml 14G2a that we have reported \[[@pone.0236115.ref025]\]. Groups were compared by one-way ANOVA with post hoc analyses by Fishers LSD or repeated measures ANOVA with post hoc analyses by Bonferroni test. Two groups were compared using t-test, or t-test with Welch correction when variances were significantly different. We also examined differences in pain behavior among groups by calculating the area under the curve (AUC, hyperalgesia index) for each animal, which compresses the data for the entire time course for into a single data point. Paw withdrawal response (pain behavior data), polyamine and DFMO concentration are presented as the mean and standard error of all observed values at each timepoint. Serum polyamine levels were derived from duplicate measurements of individual samples. Data were analyzed using OriginPro 2018 and Graphpad Prism; p\<0.05 was considered statistically significant.

Results {#sec011}
=======

Anti-GD2 treatment induces a dose dependent allodynia that can be reduced by DFMO {#sec012}
---------------------------------------------------------------------------------

We have previously reported that an intravenous injection of 1 mg/kg 14G2a, a dosage within the range used in children, into rat tail vein induces withdrawal responses at pressures that are normally innocuous, indicative of pain behavior (allodynia) \[[@pone.0236115.ref025]\]. Consistent with this finding, animals injected with both 1 mg/kg (N = 14) and 2 mg/kg (N = 6) 14G2a developed significant allodynia with similar onsets of development (latency) within 1-hour post i.v. injection, and with maximum allodynia occurring about 3-5hs post-injection ([Fig 1A and 1C](#pone.0236115.g001){ref-type="fig"}, p\<0.001, one-way repeated measures ANOVA). For the 1 mg/kg dose of 14G2a, thresholds remained significantly lower than pre-injection levels at all time points through 8h while by 24h, it was no longer different from the pre-injection control values ([Fig 1A](#pone.0236115.g001){ref-type="fig"} and [Table 1](#pone.0236115.t001){ref-type="table"}). In contrast, sensitivity to touch remained significantly different than basal levels even at 24h in the 2 mg/kg 14G2a treated animals, the latest time-point investigated, demonstrating a longer duration of effect ([Fig 1C](#pone.0236115.g001){ref-type="fig"} and [Table 1](#pone.0236115.t001){ref-type="table"}). At every time point measured from 1h until the end of the study, a qualitative examination of the data indicates that animals given 2 mg/kg had lower average withdrawal thresholds (more allodynia) than those given the lower dose. A comparison of the hyperalgesia indexes of the two 14G2a dose groups in the absence of DFMO over both the first 8h (AUC8h: 68.0 ± 7.2 (1 mg/kg/0% DFMO, N = 14) vs 46.6 ± 3.7 (2 mg/kg/0% DFMO, N = 6), p\<0.02, t-test), as well as the entire 24h experimental period (AUC24h: 216.9 ± 21.0 (1 mg/kg/0% DFMO, N = 14) vs. 94.8 ± 10.6 (2 mg/kg/0% DFMO, N = 6), p\<0.001, t-test), confirms the significantly greater allodynia at the higher 14G2a dosage. These data demonstrate a dose-dependent increase in pain behavior elicited by 14G2a, whereas an increased dosage of 14G2a increased the magnitude and duration of the pain behavior without affecting the latency of onset.

![Rat paw withdrawal responses after injection with anti-GD2.\
**A)** Rat paw withdrawal responses (allodynia, sensitivity) over the course of the study in animals drinking water without DFMO after a 1 mg/kg injection of 14G2a (p\<0.001, one-way Repeated Measures ANOVA), in animals drinking water containing 0.25% and 0.5% DFMO (both p\<0.005, one-way Repeated Measures ANOVA), and in animals drinking water containing 1% DFMO (p\>0.05, one-way Repeated Measures ANOVA); **B)** The AUC after a 1 mg/kg injection of 14G2a and each DFMO concentration for the first 8h (AUC 8h) (p = 0.077, One-way ANOVA) (\*p\<0.05, 0% DFMO vs. 1% DFMO, post-hoc Fishers LSD test); **C)** Rat paw withdrawal responses in animals injected with 2 mg/kg injection of 14G2a and allowed to drink water without or with 1% DFMO (both conditions versus pre-treatment, p\<0.001, one-way Repeated Measures ANOVA); **D)** The AUC after a 2 mg/kg injection of 14G2a for the entire 24h (AUC 24h) (\^p\<0.01, t-test).](pone.0236115.g001){#pone.0236115.g001}
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###### Bonferroni comparisons vs pre-injections.

![](pone.0236115.t001){#pone.0236115.t001g}

  1 mg 14G2a       2 mg 14G2a                                             
  ---------------- ------------ ---------- --------- --------- ---------- ----------
  **0h vs 0.5h**   p\<0.05      p\>0.05    p\>0.05   p\>0.05   p\>0.05    p\>0.05
  **0h vs 1h**     p\<0.001     p\>0.05    p\>0.05   p\>0.05   p\<0.001   p\<0.05
  **0h vs 2h**     p\<0.001     p\<0.001   p\>0.05   p\>0.05   p\<0.001   p\<0.001
  **0h vs 3h**     p\<0.001     p\<0.05    p\>0.05   p\>0.05   p\<0.001   p\<0.001
  **0h vs 4h**     p\<0.001     p\<0.05    p\<0.05   p\>0.05   p\<0.001   p\<0.001
  **0h vs 5h**     p\<0.001     p\<0.05    p\<0.05   p\>0.05   p\<0.001   p\<0.001
  **0h vs 8h**     p\<0.001     p\>0.05    p\>0.05   p\>0.05   p\<0.001   p\<0.001
  **0h vs 24h**    p\>0.05      p\>0.05    p\>0.05   p\>0.05   p\<0.001   p\<0.001

Post-hoc Bonferroni p values following one-way repeated measures ANOVA (see text and [Fig 1](#pone.0236115.g001){ref-type="fig"}) of each testing condition at each timepoint versus pretreatment.

Prior to comparing allodynic profiles of rats given anti-GD2 and DFMO, we first established that pretreatment with DFMO did not affect baseline withdrawal thresholds in otherwise untreated animals (T = 0h, [Fig 1A and 1C](#pone.0236115.g001){ref-type="fig"}). We next compared anti-GD2 induced pain behavior in animals administered water-containing various concentrations of DFMO. Animals in the 0.25% and 0.5% DFMO groups (N = 10 each) continued to exhibit significant pain behavior in response to injection with 1 mg/kg 14G2a ([Fig 1A](#pone.0236115.g001){ref-type="fig"}, 0.25% (p\<0.001) and 0.5% (p\<0.005), one-way repeated measures ANOVA). Although sensitivity persisted in animals' drinking water with 0.25% and 0.5% DFMO, pain-behavior was nevertheless reduced, particularly at the beginning and end of the experiment ([Table 1](#pone.0236115.t001){ref-type="table"}). In animals given the higher concentration of 1% DFMO (N = 8), withdrawal thresholds were not significantly different from pre-injection levels at any timepoint (p\>0.05, repeated measures ANOVA, [Fig 1A](#pone.0236115.g001){ref-type="fig"} and [Table 1](#pone.0236115.t001){ref-type="table"}).

We also evaluated the effect of DFMO on allodynia over the entire experiment using an AUC analysis ([Fig 1B](#pone.0236115.g001){ref-type="fig"}). Based on the duration of the 14G2a-induced allodynia in the non-DFMO watered animals, we limited the AUC analysis of the 1 mg/kg dosage to the first 8h, the time period during which 14G2a produced significant allodynia. After normalizing the data in this manner, the differences among the four treatment groups did not reach statistical significance (p = 0.077, ANOVA), though post-hoc and t-test analyses both document that there was a significant difference between the control (non-DFMO) group and the 1% DFMO group (p\<0.05). The lower concentrations of DFMO, which both reduced the magnitude and duration but did not fully abrogate the allodynia ([Fig 1A](#pone.0236115.g001){ref-type="fig"} and [Table 1](#pone.0236115.t001){ref-type="table"}), failed to demonstrate significant differences from the non-DFMO group using this normalization approach ([Fig 1B](#pone.0236115.g001){ref-type="fig"}).

In animals allowed to drink water without (N = 6) or with (N = 12) 1% DFMO and injected with 2 mg/kg 14G2a, the antibody induced significant allodynia under both conditions (both p\<0.001, one-way repeated measures ANOVA, [Fig 1C](#pone.0236115.g001){ref-type="fig"}). However, in contrast to the animals injected with 1 mg/kg 14G2a, 1% DFMO reduced but did not completely prevent pain behavior, with thresholds remaining significantly lower than pre-injection levels at all timepoints from 1h on ([Table 1](#pone.0236115.t001){ref-type="table"}). As allodynia in this group remained significant even at the end of the experiment, we utilized the entire 24h time course for an AUC analysis. The significantly greater AUC in the 1% DFMO versus the non-DFMO group (p\<0.01, t-test, [Fig 1D](#pone.0236115.g001){ref-type="fig"}) clearly demonstrates that there is a decrease in overall allodynia in the animals drinking water plus DFMO despite the increased pain burden in the control group.

These data demonstrate a dose-dependent increase in pain behavior induced by 14G2a, where an increased dosage of 14G2a increased the magnitude and duration of the pain behavior without significantly affecting the latency of onset. More importantly, these data demonstrate the ability of DFMO to reduce the magnitude and duration of significant pain behavior and imply that increased dosage of anti-GD2 treatment may be made tolerable in the presence of DFMO co-administration.

Serum concentrations of DFMO {#sec013}
----------------------------

Animals were allowed to freely drink water containing different concentrations of DFMO (0.25%, 0.5% and 1%) or water alone. All animals, regardless of treatment, looked healthy without any evidence of lethargy and showed normal weight gain over the course of the study. There were no signs of dehydration in any of the groups. At the end of the study serum levels of DFMO were determined to compare how the administered concentrations were reflected in the blood of the treated animal. No HPLC peak for DFMO was seen in the control animals, as expected. In contrast, all animals given DFMO in their water had a positive HPLC peak, with mean ± SEM DFMO levels of 17. 8 +/- 5.1 μM (N = 10), 16.5 +/- 2.7 μM (N = 10) and 35.3 +/- 5.4 μM (N = 20) for the 0.25%, 0.5% and 1% groups respectively ([Fig 2](#pone.0236115.g002){ref-type="fig"}). ANOVA analysis of the three groups that received DFMO in their water demonstrated there were significant differences between the groups (p\<0.05), with post-hoc comparisons indicating that differences were between either of the two lower DFMO concentrations and the 1% group (p\<0.05 each), while the 0.25% and 0.5% DFMO groups were not different from each other.

![DFMO levels in rat blood.\
Serum DFMO levels at the end of the study (mean ± SEM). \*p\<0.05, 0.25% and 0.5% vs. 1% DFMO, post-hoc Fishers LSD test.](pone.0236115.g002){#pone.0236115.g002}

Changes in serum polyamines by DFMO {#sec014}
-----------------------------------

We compared polyamine levels in three untreated (non-DFMO watered, non-14G2a) animals versus non-DFMO watered animals injected with both doses of 14G2a. Though mean putrescene levels were slightly higher in animals injected with 2 mg/kg than 1 mg/kg, and mean spermidine and spermine levels were slightly higher in 14G2a treated versus untreated animals, a comparison of each of the three polyamines at untreated, 1 mg/kg and 2 mg/kg 14G2a revealed that none of these changes reached significance ([Fig 3](#pone.0236115.g003){ref-type="fig"}, ANOVA each polyamine, p\>0.05).

![Polyamine levels in rat blood after anti-GD2 injections.\
Polyamine levels were measured in serum from rats injected with 0, 1 or 2 mg/kg 14G2a and allowed to drink water with various concentrations of DFMO and are presented as mean ± SEM. **A)** Putrescine levels were reduced by DFMO in animals injected with 1 mg/kg (p\<0.001, one-way ANOVA). \*p\<0.01, each vs. 0% DFMO, Fishers LSD post-hoc analysis; \^p\>0.05, 1 mg/kg/1% DFMO vs. 2 mg/kg/1% DFMO, t-test; **B)** Spermidine levels were significantly reduced by 1% DFMO in the animals injected with 1 mg/kg 14G2a (p\<0.05, t-test); **C)** Spermine levels were not affected by DFMO treatment (p\>0.05, t-test).](pone.0236115.g003){#pone.0236115.g003}

As DFMO is known to reduce serum polyamine levels, and increased serum polyamines are observed in some clinical pain states and various manipulations aimed at reducing serum polyamines reduce pain behavior, we measured serum polyamines following both dosages of 14G2a and DFMO pretreatment. Consistent with the known actions of DFMO, serum putrescine levels were significantly reduced in the 0.25%, 0.5% and 1% groups of DFMO-treated animals following 1 mg/kg 14G2a compared to animals not given DFMO ([Fig 3A](#pone.0236115.g003){ref-type="fig"}, 0.68 μM ± 0.09 (0%, N = 14), 0.35 ± 0.04 μM (0.25%, N = 10), 0.31 ± 0.02 μM (0.5%, N = 10) and 0.29 ± 0.03μM (1%, N = 7); ANOVA p\<0.001). Post-hoc analyses demonstrated the mean putrescine levels of each of the DFMO groups were significantly lower than the untreated group but not different from each other, suggesting levels are already maximally decreased at the lower concentrations of DFMO. Putrescine is the first polyamine synthesized by ODC and thus it would be expected to be most affected by ODC inhibition. Spermidine is synthesized next in the polyamine cascade and was also significantly lower in the 1 mg/kg 14G2a, 1% DFMO-treated animals ([Fig 3B](#pone.0236115.g003){ref-type="fig"}, mean ± SE, 1.61 μM ± 0.11 (0%, N = 14) and 0.96 ± 0.24 μM (1%, N = 8); p\<0.05, t-test). In contrast, no changes in spermine were observed between animals injected with 1 mg/kg and drinking water without or with 1% DFMO (0.10 ± 0.01 μM (0%, N = 14) vs 0.12 ± 0.02 μM (1%, N = 8) (p\>0.05, [Fig 3C](#pone.0236115.g003){ref-type="fig"}).

We next compared putrescine levels in control and 1% DFMO animals given the higher dosage of 14G2a. Pretreatment with 1% DFMO not only significantly reduced mean putrescine levels in the 2 mg/kg treated animals (0.97+/- 0.16 (0%, N = 6) vs 0.28+/- 0.04 (1%, N = 12), p\<0.01. t-test), but reduced the mean to levels indistinguishable from animals injected with 1 mg/kg 14G2a/1% DFMO (p\>0.05, t-test) ([Fig 3A](#pone.0236115.g003){ref-type="fig"}). This suggests that 1% DFMO achieved maximal reduction of putrescine at both 14G2a dosages.

Discussion {#sec015}
==========

Anti-GD2 therapy with dinutuximab has been validated as efficacious in the treatment of children with high risk neuroblastoma in remission and with relapsed and refractory disease, although there remain a number of patients who do not respond and/or relapse \[[@pone.0236115.ref004], [@pone.0236115.ref005], [@pone.0236115.ref007], [@pone.0236115.ref008]\]. Additional therapeutic approaches and/or combination therapies are clearly needed to further improve outcome. However, dose-escalation of dinutuximab is challenging due to the severe pain caused by the anti-GD2. Patients suffer from severe visceral pain and whole-body allodynia that begins within an hour after initiation of dinutuximab infusion \[[@pone.0236115.ref026]\].

In the rat, GD2 ganglioside is located on Schwann cells located along the peripheral nerve fibers \[[@pone.0236115.ref027]\]. Systemic administration of either a murine (14G2a) or a murine/human chimeric (ch14.18, (dinutuximab)) antibody elicits reduced mechanical withdrawal threshold, i.e., allodynia, and whole-body touch evoked agitation \[[@pone.0236115.ref025], [@pone.0236115.ref028]\]. Coincident with antibody-induced pain behavior in the rat model, distal C fibers that are surgically disconnected from their cell bodies and the central nervous system, but are still attached to the skin, develop high frequency spontaneous activity after anti-GD2 injection \[[@pone.0236115.ref029]\]. This may be due to either an excitatory effect of the 14G2a on the peripheral nerve fiber or to the cutaneous nerve endings ([Fig 4](#pone.0236115.g004){ref-type="fig"}). As the pain behavior is blocked by systemic pre-treatment with a complement C5 antagonist \[[@pone.0236115.ref030]\], the assumption is that the nociceptive actions produced by anti-GD2 therapy occurs downstream of an antibody/antigen interaction on the non-myelinating Schwann cells that surround the C fibers. The situation is more complicated clinically, where malignancies enriched with the GD2 ganglioside, e.g. neuroblastoma, provide more substrate for this reaction. The preponderant localization of neuroblastoma tumors in proximity to visceral C fibers may be the proximate cause of the particularly intense visceral pain seen in these patients.

![Model of pain pathways from anti-GD2 and polyamines.](pone.0236115.g004){#pone.0236115.g004}

Potential mechanisms by which pain behavior may be modulated by 14G2a and DFMO. Polyamine (PA) injection into the skin \[[@pone.0236115.ref016]\] or around the spinal cord \[[@pone.0236115.ref031]\] both induce pain behavior while DFMO decreases pain behavior \[[@pone.0236115.ref016]\]. Systemic administration of anti-GD2 induces activation of C fibers and also causes an increase in pain behavior \[[@pone.0236115.ref025], [@pone.0236115.ref028], [@pone.0236115.ref029]\]. Nerve injury increases ODC and PA at the dorsal root ganglia (DRG) \[[@pone.0236115.ref032]\]. In the skin, pain behavior is blocked by pretreatment with antagonists to TRPV1R \[[@pone.0236115.ref033]\], which are found on a subpopulation of peptide (substance P) and calcitonin gene-related protein (CGRP)) expressing C fibers. Importantly, functional elimination of these fibers also blocks anti-GD2-induced pain behavior \[[@pone.0236115.ref034]\]. *Spinal* administration of antagonists to the NMDAR, a glutamate receptor subtype, were highly effective in blocking spinal polyamine induced pain behavior \[[@pone.0236115.ref031]\], though the *peripheral* co-administration of NMDAR antagonists with polyamines had no effect on the evoked pain behavior \[[@pone.0236115.ref033]\]. Green lines are excitatory, red lines are inhibitory.

Our data confirm that anti-GD2 is evoking a pain response in the absence of tumors, which is consistent with preclinical studies from our group \[[@pone.0236115.ref025]\] and the pain observed in neuroblastoma patients without detectable disease who were receiving maintenance therapy of anti-GD2 \[[@pone.0236115.ref004]\]. We hypothesized that even in the absence of tumor cells, treatment with antibodies against GD2 may be directly or more probably indirectly activating the ornithine pathway and newly synthesized polyamines and/or released intracellular polyamines may be contributing to the observed pain. This assumption was supported by the work of Mäntyselkä et al \[[@pone.0236115.ref035]\], who showed that ornithine levels in adults with persistent musculoskeletal pain were elevated compared to patients with non-persistent pain, and both were higher than those seen in a control population. Other studies have also demonstrated elevated plasma ornithine in patients with complex regional pain syndrome compared to that of ornithine levels in controls \[[@pone.0236115.ref036]\]. Downstream polyamine involvement in several pro-nociceptive receptors/systems is also well substantiated. Spermine and spermidine induce a biphasic dose-dependent activation/inactivation of NMDA receptors (NMDAR) in spinal cord and cerebral cortex \[[@pone.0236115.ref037]\]. Similarly, spinal spermine induced biphasic effects on pain behavior with pronounced hyperalgesia at higher doses \[[@pone.0236115.ref031]\]. Spinal polyamine elicited pain behavior was blocked by a variety of NMDA receptor antagonists, including notably ifenprodil, an antagonist of the GluN2B subunit \[[@pone.0236115.ref031], [@pone.0236115.ref038]\]. It is unknown whether these spinal actions are due to presynaptic or postsynaptic actions. However, since the antibody does not cross the blood brain barrier in an animal with no inflammation or malignancies, the initial step in antibody-induced allodynia in our study is likely due to an action at or in the immediate vicinity of the peripheral nerve.

The novel findings from this study are that 1% DFMO treatment significantly reduced anti-GD2-induced pain behavior and that this reduction was seen in the face of antibody dose escalation, thus our original hypothesis was confirmed. Results concerning our second contention that there was an association between magnitude of pain behavior and plasma levels of polyamines are less clear. Blood sampling was done at the end of the study, 24 hours after the GD2 injection, to minimize confounding effects on animal behavior. As animals remained on water containing DFMO during the entire time, polyamine levels would remain suppressed even as allodynia waned. However, it is unlikely that this confounded their correlation with peak allodynia as the animals had already been on DFMO for 7--10 days. Differences between the peak reduction in pain and PA levels might reflect different dose response curves for actions of DFMO on pain versus polyamine reduction. It is notable that in two independent studies of pain and polyamine levels, no direct correlation between expressed pain magnitude and measured ornithine was observed \[[@pone.0236115.ref016], [@pone.0236115.ref036]\]. Our study also does not exclude the possibility of discrete local changes in polyamine levels after anti-GD2 injection, especially considering the limited expression of the GD2 antigen outside of nerve fibers in the absence of cancer, and the fact that nerve injury has been shown to be associated with an increase in ODC and polyamines at the dorsal root ganglia \[[@pone.0236115.ref032], [@pone.0236115.ref039]\]. What we can conclude from our study is that DFMO treatment in rats given anti-GD2 produced a clear decrease in pain and polyamines.

Actions of DFMO on pathways besides or in addition to polyamines must also be considered. Caspase-12 is considered to be pro-inflammatory and increases within the nociceptive matrix after nerve injury \[[@pone.0236115.ref040]\]. Agents such as cannabinoids and ozone which reduce ER stress reduce both pain behavior and the increase in caspase-12 \[[@pone.0236115.ref041], [@pone.0236115.ref042]\]. This is significant as DFMO has also been reported to reduce the expression of caspase-12 in some animal models involving endoplasmic reticulum stress mediation pathways \[[@pone.0236115.ref043]\]. In a study of the effects of DFMO on cardiac hypertrophy in rats, DFMO not only inhibited ODC and decreased polyamine levels, but also decreased the expression of GRP78, protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), calreticulin, and caspase-12 \[[@pone.0236115.ref043]\]. However, it is unknown if these are direct actions of DFMO or secondary actions resulting from ODC inhibition and/or decreases in polyamine levels. These studies demonstrate that the effects of DFMO on pain may go beyond ODC inhibition, and offer the possibility that the depletion of polyamines may not be the (sole) mechanism by which DFMO reduces anti-GD2 induced allodynia.

A number of clinical studies are investigating DFMO as a therapeutic adjunct to chemotherapy for patients with a number of different cancers (ClinicalTrials.gov). In particular, DFMO has already shown promise in the treatment of high-risk neuroblastoma when given during the *post*-maintenance phase when compared to historic controls \[[@pone.0236115.ref044]\]. However, this is the first study to demonstrate that DFMO may also be associated with the amelioration of the clinically observed pain induced by anti-GD2 therapy. The biologically effective anti-cancer blood levels of DFMO are in the 50--150 μM range for both adult and pediatric cancers (\[[@pone.0236115.ref015]\] and references therein). These concentrations are slightly higher than we have observed for rats on 1% DFMO, the group that showed the greatest anti-allodynic benefit. This suggests that DFMO concentrations with anti-tumor activity should be sufficient to also confer anti-allodynic benefits and are not only readily attainable, but may allow for an increase in anti-GD2 dosage as well.

Conclusion {#sec016}
==========

Currently, neuroblastoma is the only disease approved for anti-GD2 therapy. However, dinutuximab is also being investigated for use in other cancers that express GD2, such as small cell lung cancer and osteosarcoma \[[@pone.0236115.ref045]\]. DFMO is showing promise as an anti-cancer adjunct when used in combination with various chemotherapeutics and during the post-maintenance phase of ant-GD2 therapy of neuroblastoma. Thus, there may be multiple benefits of DFMO in combination with anti-GD2: 1) reduced pain allows for increased dosage and possibly increased anti-GD2 efficacy; 2) reduced pain may expand the patient population and cancer types amiable for anti-GD2 therapy; and 3) DFMO may contribute an anti-cancer benefit in addition to or independent of its anti-allodynic effect. In summary, using DFMO as an adjunct to dinutuximab may allow dose escalation for neuroblastoma patients on anti-GD2 immunotherapy and a sufficient reduction in pain such that new patient populations may utilize this therapy given the more acceptable side effect profile.

Supporting information {#sec017}
======================

###### Scheduled acquisition times of putrescine and DFMO.

Ion (m/z) transitions monitored, scheduled acquisition times (minutes), analyzer parameters (declustering (DP), entrance (EP) and collision cell (CXP) potentials) and analytical range (micromoles per liter; μL) for putrescine, difluoromethylornithine (DFMO), and stable-isotope labeled internal standards, 1,1,2,2,3,3,4,4-^2^H~8~-putrescine (d8-putrescine) and 5,5-^2^H~2~-ornitine (d2-ornithine). Numerals -1 indicate the transition used for quantification, and -2 the one used for confirmation.

(DOCX)

###### 

Click here for additional data file.

###### Putrescene and DFMO measurement by HPLC and LC-MS/MS.

(DOCX)

###### 

Click here for additional data file.

###### Putrescene, spermidine and spermine measurement by HPLC and LC-MS/MS using derivatives.

(DOCX)

###### 

Click here for additional data file.

###### The ARRIVE guidelines checklist.

(PDF)

###### 

Click here for additional data file.

###### Rat serum polyamine and DFMO levels.

(XLSX)

###### 

Click here for additional data file.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 01 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:
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2\. At this time, we request that you  please report additional details in your Methods section regarding animal care, as per our editorial guidelines. Specifically, please state the number of mice used in the study. Thank you for your attention to these requests.

3\. Please note that PLOS does not permit references to "data not shown." or \"unpublished data\". Authors should provide the relevant data within the manuscript, the Supporting Information files, or in a public repository. If the data are not a core part of the research study being presented, we ask that authors remove any references to these data.

4\. At this time, we ask that you please the product number of the DFMO obtained from Professor Patrick M. Woster in your study.

5\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

6\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The ms of Diccianni et al is directed to test the efficacy of DFMO against the allodynia induced by anti-GD2 treatment. Behavioral tests show antiallodynic effects of DFMO. Furthermore, a concomitant reduction in plasmatic levels of putrescene and spermidine was measured using high performance liquid chromatography and mass spectrometry. The objectives of the work are clear and straightforward, and the experiments seem adequately performed. The results are in line to previous reports that have shown analgesic effects of DFMO in models of pain, making them extensible to this model of anti-GD2 allodynia.

In my opinion the work is correctly made, and my unique concern about the ms is related to the insistence of the authors to justify a causal relation between antiGD2, polyamines and pain, that is not directly supported by their data. As an example "treatment with antibodies against GD2 are activating the ornithine pathway and/or releasing intracellular polyamines". Their arguments to draw this relation are reasonably explained in basis of existing literature, but they are speculative considering the data showed, and hence the authors should be more cautious and consider alternative explanations.

AntiGD2 do not increase polyamines, at least at 24h. The argument that poliamines may be elevated at early steps is reasonable, but need to be demonstrated. So the authors may consider to make an analysis of polyamines at earlier time points, this will strength their arguments. Since only 100 microlitres of plasma seem necessary for the determination, and the concentration of polyamines varies considerably between animals, if possible, the most interesting approach could be to compare the values before and after antiGD2 in the same animals for one of the polyamines. To stablish a causal relation, polyamines should be elevated from the time point that allodynia can be detected (or even before).

Alternatively, if the authors are not able to make this assay, they should give more weight to other putative explanations that are only briefly mentioned in the current version. Although it seems less likely, anti-GD2 may induce allodynia by a mechanism independent of polyamines, and DFMO may also reduce allodynia by mechanisms independent of polyamines reduction (despite being able to reduce them).

Other comments:

If possible, it would be of interest that the authors may explain how they believe that results using an acute dose of anti-GD2 can be extrapolated to long lasting treatment. Would they expect dissimilarities?

In the last sentence of the results section the authors claim that since the reduction in putrescine levels produced by 1% DFMO was similar between animals treated with 1 and 2 mg/kg of anti-GD2 "this suggests that 1% DFMO has achieved maximal reduction of putrescine at both 14G2a dosages". Since the levels of putrescine shown are not different between both dosages of anti-GD2, it is reasonable that the same concentration of DMFO had the same effect as well, and, from my point of view, it does not exclude that higher concentrations of DMFO may produce higher reductions. In addition, the variability between subjects is perhaps very strong to make this type of assumption.

ODC abbreviation need to be explained in the abstract since sometimes is read alone.

Take into account that the resolution of the figures is rather bad, even downloading them. For figures 2 A and C, perhaps may be valuable to indicate the statistical significance at the different time points, it would be more descriptive. In addition, an asterisk seems to be absent in fig 2B ("there was a significant difference only between the control (non-DFMO) group and the two DFMO groups (both p\<0.05)").

Reviewer \#2: The manuscript by Diccianni and collaborators entitled Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO reported data regarding the effect of DFMO on allodynia induced by Anti-GD2 therapy

Manuscript is quite confusing.

The authors are encouraged to more carefully develop their results along the following lines:

Authors need to choose a single dose of 14G2a to show. Why they reported both 1mg and 2 mg?

They already reported that intravenous injection of 1 mg/kg 14G2a, a

dosage within the range used in children, into rat tail vein induces withdrawal

responses at pressures that are normally innocuous, indicative of pain behavior

(allodynia) (ref 23).

0.25 and 0.5 of DFMO are reported together. It is not right to explore a dose related response. Please carefully revise.

Figure 2 need to be before figure 1

Please carefully revise all the ms to point on the major results.

Please also revise the discussion by reducing and focusing on the advance reported by the proposed study

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Apr 2020

Dear Editor and esteemed reviewers,

We thank you all for your thorough review and critique of our manuscript entitled: "Anti-GD2 induced allodynia can be reduced in rats by pretreatment with DFMO" by Diccianni et al. for consideration of publication in PLoS1 as a Research Article. We have addressed the concerns of the reviewer and present this point by point response in red in this cover letter. We have modified the results section as recommended, and have extensively rewritten the discussion. We have uploaded both a tracked and tracking accepted version of the manuscript. We hope you find this revised version acceptable for publication.

Sincerely yours,

Mitchell B. Diccianni

 

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

These links do not work. However, we have followed the correct format.

2\. At this time, we request that you please report additional details in your Methods section regarding animal care, as per our editorial guidelines. Specifically, please state the number of mice used in the study. Thank you for your attention to these requests.

The ARRIVE guidelines have been followed and an ARRIVE checklist is included in the supplemental materials. This fact is now mentioned in the Methods section (page 6) and included as S1 appendix.

We have now added a total to the methods section (page 6), while the individual breakdown of animals per treatment group remains throughout the results section.

3\. Please note that PLOS does not permit references to "data not shown." or \"unpublished data\". Authors should provide the relevant data within the manuscript, the Supporting Information files, or in a public repository. If the data are not a core part of the research study being presented, we ask that authors remove any references to these data.

These have all been removed or referenced in the revised version.

4\. At this time, we ask that you please the product number of the DFMO obtained from Professor Patrick M. Woster in your study.

Page 8: There is no product number. We have clarified with Dr. Woster and modified the phrase as follows: "DFMO was synthesized by Genzyme Corporation (Lot \#PD39CF) and graciously provided to us by Dr. Patrick Woster of the Medical University of South Carolina, Charleston, South Carolina".

5\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

See \#3 above.

6\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Added.

Comments to the Author

Reviewer\#1:

The ms of Diccianni et al is directed to test the efficacy of DFMO against the allodynia induced by anti-GD2 treatment. Behavioral tests show antiallodynic effects of DFMO. Furthermore, a concomitant reduction in plasmatic levels of putrescene and spermidine was measured using high performance liquid chromatography and mass spectrometry. The objectives of the work are clear and straightforward, and the experiments seem adequately performed. The results are in line to previous reports that have shown analgesic effects of DFMO in models of pain, making them extensible to this model of anti-GD2 allodynia.

In my opinion the work is correctly made, and my unique concern about the ms is related to the insistence of the authors to justify a causal relation between antiGD2, polyamines and pain, that is not directly supported by their data. As an example "treatment with antibodies against GD2 are activating the ornithine pathway and/or releasing intracellular polyamines". Their arguments to draw this relation are reasonably explained in basis of existing literature, but they are speculative considering the data showed, and hence the authors should be more cautious and consider alternative explanations.

The reviewer is correct in that our data document that pain is prevented and PA levels reduced, but the relationship between the two actions is less than clear. Inhibition of ODC and the subsequent reduction in polyamine levels, in particular putrescene, is the best characterized role for DFMO. Other actions of DFMO are either less characterized or may be secondary actions of ODC inhibition and polyamine depletion. However, both reviewers felt it was necessary to expand these points, which we do on pages 19-21.

We modified the sentence on page 19 "...treatment with antibodies against GD2 are activating the ornithine pathway..." to the more speculative "We hypothesized that treatment with antibodies against GD2 may be activating the ornithine pathway" and rewrote the paragraph surrounding.

AntiGD2 do not increase polyamines, at least at 24h. The argument that poliamines may be elevated at early steps is reasonable, but need to be demonstrated. So the authors may consider to make an analysis of polyamines at earlier time points, this will strength their arguments. Since only 100 microlitres of plasma seem necessary for the determination, and the concentration of polyamines varies considerably between animals, if possible, the most interesting approach could be to compare the values before and after antiGD2 in the same animals for one of the polyamines. To stablish a causal relation, polyamines should be elevated from the time point that allodynia can be detected (or even before).

Alternatively, if the authors are not able to make this assay, they should give more weight to other putative explanations that are only briefly mentioned in the current version. Although it seems less likely, anti-GD2 may induce allodynia by a mechanism independent of polyamines, and DFMO may also reduce allodynia by mechanisms independent of polyamines reduction (despite being able to reduce them).

The reviewer is also correct in that at least at 24h, our data fail to show an increase in polyamine levels after anti-GD2 injections. Obtaining blood at peak allodynia would have required either a chronically placed catheter to withdraw blood, or infraorbital blood sampling. The first method would have required a larger sample to be withdrawn to account for the dead space in the catheter and would require the animals to be housed singly (they chew on each other's catheters), the second method is likely to have influenced behavioral testing and would likely have caused problems with the animal care committee, which is reluctant to approval for additional procedures in studies with maintained allodynia/pain. Since our primary clinically-motivated objective was to determine whether DFMO would reduce anti-GD2 allodynia, we did not perform mid-experiment blood sampling as we did not want to risk jeopardizing these behavioral results.

That said, we are not sure the results would have been any different. The animals were on DFMO containing water for 7-10 days. We expect polyamines would have been suppressed and have remained suppressed prior to and during the study. This is discussed on pages 20-21

In the original version, we discussed "alternative" mechanisms only briefly. For this revision, we have expand the discussion of "other putative explanations" (i.e. speculate more, page 20-21) while balancing Reviewer's 2 concern to focus the discussion.

We have edited "...this is the first study to demonstrate that depletion of polyamines..." to "...this is the first study to demonstrate that DFMO ...") on page 22.

Other comments:

If possible, it would be of interest that the authors may explain how they believe that results using an acute dose of anti-GD2 can be extrapolated to long lasting treatment. Would they expect dissimilarities?

Another excellent point! Our introduction (page 3) explains the limits of anti-GD2 therapy. We have added a clinical study of DFMO in neuroblastoma to the discussion (pg 22) and a summary in the conclusion as to why the two could be better together than alone (pg 22-23).

In the last sentence of the results section the authors claim that since the reduction in putrescine levels produced by 1% DFMO was similar between animals treated with 1 and 2 mg/kg of anti-GD2 "this suggests that 1% DFMO has achieved maximal reduction of putrescine at both 14G2a dosages". Since the levels of putrescine shown are not different between both dosages of anti-GD2, it is reasonable that the same concentration of DMFO had the same effect as well, and, from my point of view, it does not exclude that higher concentrations of DMFO may produce higher reductions. In addition, the variability between subjects is perhaps very strong to make this type of assumption.

True. Putrescene levels seem to be maximally decreased at the lowest \[DFMO\] used while the relief of allodynia show a relationship with \[DFMO\] used (Figure 1A). Thus a higher concentration of DFMO may suppress allodynia further, something particularly beneficial if a higher dose of anti-GD2 is to be used. However, DFMO is bitter. In human studies, the DFMO is given mixed with juice to increase palatability. Our study design required the passive consumption of DFMO-containing water. The increased bitterness of a 2% DFMO solution may result in the animals drinking less. In this case, the effects of \[DFMO\] at 2% may be only slightly or not at all different than at 1%.

ODC abbreviation need to be explained in the abstract since sometimes is read alone.

OK, this has been added.

Take into account that the resolution of the figures is rather bad, even downloading them.

OK-we used PACE this time around.

For figures 2 A and C, perhaps may be valuable to indicate the statistical significance at the different time points, it would be more descriptive. In addition, an asterisk seems to be absent in fig 2B ("there was a significant difference only between the control (non-DFMO) group and the two DFMO groups (both p\<0.05)").

We did not include asterisks for all the individual points as it made the figure very messy. The text states (pg 12) and a new S1 Table shows where significance lies.

A single asterisk in Fig 2B (now Figure 1B per Reviewer 2's critique) is correct.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Reviewer \#2: The manuscript by Diccianni and collaborators entitled Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO reported data regarding the effect of DFMO on allodynia induced by Anti-GD2 therapy

Manuscript is quite confusing.

We are sorry the reviewer found the manuscript quite confusing. We tried to present a manuscript that was concise and straight forward: Oral DFMO reduces anti-GD2 induced allodynia (novel finding); DFMO reduces polyamine levels (as expected); the reduction in polyamines levels did not directly correlate with the reduction of allodynia (novel finding requiring some speculation). In this revision, we have tried to clarify these thoughts further.

The authors are encouraged to more carefully develop their results along the following lines:

Authors need to choose a single dose of 14G2a to show. Why they reported both 1mg and 2 mg? They already reported that intravenous injection of 1 mg/kg 14G2a, a dosage within the range used in children, into rat tail vein induces withdrawal responses at pressures that are normally innocuous, indicative of pain behavior (allodynia) (ref 23).

We strongly disagree with this thought. Dinutuximab is an excellent but imperfect therapeutic for high risk neuroblastoma treatment. However, late failures occur. Higher dosages cannot be given due to the toxicity profile. In particular, whole body, opiate resistant allodynia/pain prevents an increase in dinutuximab dosage. We show in this manuscript that not only does an increase in anti-GD2 cause more allodynia, but this enhanced allodynia can be attenuated by DFMO. When given in combination, DFMO has the potential to allow anti-GD2 to be used at increased dosages. This is a major conclusion.

0.25 and 0.5 of DFMO are reported together. It is not right to explore a dose related response. Please carefully revise. Figure 2 need to be before figure 1

We have ungrouped the data and swapped the order of the first two figures.

Please carefully revise all the ms to point on the major results.

Please also revise the discussion by reducing and focusing on the advance reported by the proposed study.

We have extensively revised the discussion to focus more but, in deference to reviewer \#1, have added role for DFMO and anti-GD2 therapy (page 22) and speculate on alternative mechanisms of action (page 21).

10.1371/journal.pone.0236115.r003
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PLOS ONE

Dear Dr- Diccianni,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 26 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The revised version of the ms of Diccianni et al entitled "Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO" tested the validity of DFMO against the allodynia induced by anti-GD2, a pharmacological treatment for neuroblastoma. They show that animals allowed to drink water with DFMO showed reduced nociceptive behaviors after anti-GD2 treatment and reduced levels of polyamines at 24 hours. Previous reports have shown analgesic effects of DFMO as well as the relation between polyamines and pain. The use of DFMO can provide a benefit for patients treated with anti-GD2.

I have some concerns about statistical analysis. Now seems clear that comparisons between three or more groups were always done using One-way ANOVAs (please include "One-way" in methods). The authors may consider to include the degrees of freedom and the statistic's values, in addition to the p value. Some of the interpretations made are perhaps not adequate considering the analysis done and other test (perhaps Two-way ANOVA) that can compare different treatments should be used to support the description of some results:

\- Page 11/31 "At every time point measured from 1h until the end of the study, animals given 2 mg/kg had lower average withdrawal thresholds (more allodynia) than those given the lower dose" and "These data demonstrate a dose dependent increase in pain behavior elicited by 14G2a, whereas an increased dosage of 14G2a increased the magnitude ... of the pain behavior ..." what test was used to support these commentaries.

\- Page12/31 "exhibit significant pain behavior after injection with 1 mg/kg 14G2a ..., though sensitivity was reduced ... relative to non-DFMO watered animals" Please include the test used to affirm that sensitivity was reduced.

\- Figure1, legend page 11/31, "both conditions versus pre-treatment" and page 12-13/31 "withdrawal thresholds were not significantly different from pre-injection levels at any timepoint (p\>0.05, repeated measures ANOVA" ANOVA compares the means of ALL groups, no specifically versus pre-treatment.

\- Page 13/31 "DFMO again significantly attenuated allodynia (p\<0.001, one-way repeated measures ANOVA" If the authors want to compare the results with or without DFMO (in order to say that attenuates allodynia) they should other type of analysis comparing both treatments (14G2a with and without DFMO).

\- Other questions related to statistic: Figure1, legend page 11/31, "1 mg/kg injection of 14G2a (both p\<0.001," what "both" means and "\*p\<0.05 versus 0% DFMO only" what versus 0%?. Page 12/31 "N=14, p\<0.001," why including N=14? What does p\<0.001 stand for?

The objective two "determine if there is an association between plasma levels of polyamines and magnitude of pain behavior" is problematic. Results from animals treated with 14G2a (but not with DFMO) and controls showed no change at 24h and no earlier time points were analyzed as a proof of concept for this relation. In addition, the authors now indicate that a local change might take place (even during DFMO treatment) suggesting that plasma measurement could be an incorrect way to stablish a causal relation between polyamines and anti GD2 induced pain. These two arguments make difficult to support the speculation of such association, and the inclusion of both effects together, for example in the abstract "Administration of DFMO attenuated the enhanced sensitivity. Consistent with the known actions of DFMO on ornithine decarboxylase (ODC), serum putrescene and spermidine levels were significantly reduced by DFMO", may give an incorrect idea of what the work does really demonstrate and confound the reader.

In the new version, the results are even more complicated including statistics at different time points and concentrations, and some of them seem repeated in figure legends, including statistics. The authors may explore other forms of writings the results in a more clear and direct way and take advantage of visual support (figures-tables) to discharge this section. Consider to include it inside the manuscript, better than in supplementary material, since it is something relevant and helpful for the reader.

After rewriting the discussion, these sentences "Spermine and spermidine induce a biphasic dose dependent activation/inactivation of NMDA receptors (NMDAR) on cortical neurons and induce pain behavior that can be blocked with NMDAR antagonists (33, 34). It is unknown whether these spinal actions are due to presynaptic or postsynaptic actions." may not be correct. Neither of these works seem to look at the spinal cord. Ref 34 is a study at a peripheral level, and, if fact, shows that NMDAR are not implicated in the nociceptive actions of polyamines (as the authors indicate in fig 4). Perhaps the work by Kolhekar et al. 1994 (Neuroscience 63(4):925-36) could be more adequate to support their affirmation. But anyway the authors must be attentive to this.

Minors:

In page 7/31 is written isoflorane instead of isoflurane

In page 10/31 is written Prizm instead of Prism

Reviewer \#2: Authors reply to the observations. please spell out all the abbreviations the first time they appear

Ex in the abstract DFMO is spelled out the second time please correct.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

10 Jun 2020

Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The revised version of the ms of Diccianni et al entitled "Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO" tested the validity of DFMO against the allodynia induced by anti-GD2, a pharmacological treatment for neuroblastoma. They show that animals allowed to drink water with DFMO showed reduced nociceptive behaviors after anti-GD2 treatment and reduced levels of polyamines at 24 hours. Previous reports have shown analgesic effects of DFMO as well as the relation between polyamines and pain. The use of DFMO can provide a benefit for patients treated with anti-GD2.

• I have some concerns about statistical analysis. Now seems clear that comparisons between three or more groups were always done using One-way ANOVAs (please include "One-way" in methods). The authors may consider to include the degrees of freedom and the statistic's values, in addition to the p value. Some of the interpretations made are perhaps not adequate considering the analysis done and other test (perhaps Two-way ANOVA) that can compare different treatments should be used to support the description of some results:

"One-way" has been added to our ANOVAs.

Regarding the time compressed AUC behavior data, the use of AUC is quite common for this type of data and allows us to perform within and between comparisons similar to that of the two-way ANOVA. This analysis is forgiving of individual variations in the behavioral time courses among animals as well as allowing for differences in Ns.

• Page 11/31 "At every time point measured from 1h until the end of the study, animals given 2 mg/kg had lower average withdrawal thresholds (more allodynia) than those given the lower dose" and "These data demonstrate a dose dependent increase in pain behavior elicited by 14G2a, whereas an increased dosage of 14G2a increased the magnitude ... of the pain behavior ..." what test was used to support these commentaries.

This qualitative observation is supported by a comparison of the AUCs at different doses of 14G2a without DFMO compared by t-tests (page 11).

• Page12/31 "exhibit significant pain behavior after injection with 1 mg/kg 14G2a ..., though sensitivity was reduced ... relative to non-DFMO watered animals" Please include the test used to affirm that sensitivity was reduced.

This is part of the repeated measures ANOVA (clarified in the sentence). We now also reference Table 1 (formerly S1 Table) for added clarification.

• Figure1, legend page 11/31, "both conditions versus pre-treatment" and page 12-13/31 "withdrawal thresholds were not significantly different from pre-injection levels at any timepoint (p\>0.05, repeated measures ANOVA" ANOVA compares the means of ALL groups, no specifically versus pre-treatment.

Legend page 11/31: Both conditions refers to the fact that both 0%/2mg and 1%/2 mg were significantly different than pretreatment by repeated measures ANOVA, as stated.

page 12-13/31: The second point of concern deals solely with 1 mg/kg and 1% DFMO. Under these conditions, a repeated measures ANOVA analysis was non-significant, demonstrating that withdrawal sensitivity was completely attenuated at all time points. This is also exactly what is stated and the point we wanted to make.

• Page 13/31 "DFMO again significantly attenuated allodynia (p\<0.001, one-way repeated measures ANOVA" If the authors want to compare the results with or without DFMO (in order to say that attenuates allodynia) they should other type of analysis comparing both treatments (14G2a with and without DFMO).

We have clarified this sentence.

• Other questions related to statistic: Figure1, legend page 11/31, "1 mg/kg injection of 14G2a (both p\<0.001," what "both" means and "\*p\<0.05 versus 0% DFMO only" what versus 0%?. Page 12/31 "N=14, p\<0.001," why including N=14? What does p\<0.001 stand for?

We removed the word "both".

\*p\<0.05 versus 0%, the asterisk refers to 0% vs. 1% in Figure 1B. We have added text to additionally clarify this point.

The N=14 has been removed and the rest of the sentence has been clarified.

• The objective two "determine if there is an association between plasma levels of polyamines and magnitude of pain behavior" is problematic. Results from animals treated with 14G2a (but not with DFMO) and controls showed no change at 24h and no earlier time points were analyzed as a proof of concept for this relation. In addition, the authors now indicate that a local change might take place (even during DFMO treatment) suggesting that plasma measurement could be an incorrect way to stablish a causal relation between polyamines and anti GD2 induced pain. These two arguments make difficult to support the speculation of such association, and the inclusion of both effects together, for example in the abstract "Administration of DFMO attenuated the enhanced sensitivity. Consistent with the known actions of DFMO on ornithine decarboxylase (ODC), serum putrescene and spermidine levels were significantly reduced by DFMO", may give an incorrect idea of what the work does really demonstrate and confound the reader.

We stated the objective we set out to test. Allodynia and DFMO and their relationship with polyamine levels. 14G2a induced allodynia, an expected observation based on our published results and clinical observations. DFMO reduced polyamine levels. An expected finding. DFMO reduced allodynia. A novel finding and one of potential great significance and the determination of which was the PRIMARY objective of the study. However, despite DFMO reducing both PA and allodynia, their relationship was less than clear, requiring some speculation. One of those speculations is regarding local polyamine levels. This makes a lot of sense when one remembers the limited expression of GD2 to "...peripheral nerves, elements of the central nervous system, and skin melanocytes (2). (Page 4/31) In contrast, many cancer cells including neuroblastoma express GD2 on their surface (3)." (Page 4/31). Polyamines and ODC, in contrast, will be present in every cell, and serum polyamines abundant. DFMO will reduce both systemic and local levels of PAs. 14G2a, on the other hand, would be expected to only have actions at the GD2 antigen. Thus any increase in PA by anti-GD2 may be only at the local level and may not elevated to sufficient levels systemically and, in contrast to the decrease by DFMO, may not be detected in the serum by our assay. Since we don't know if this is true or not, we added "local levels" as a very reasonable speculation.

To avoid any misunderstanding, we have modified the abstract to reflect that despite a significant decrease in anti-GD2 induced allodynia by DFMO, and despite a significant decrease in PA levels by DFMO, there lacked a conclusive relationship between the decrease in PA and the attenuation of anti-GD2 induced pain by DFMO "Abstract Results: ...Consistent with the known actions of DFMO on ornithine decarboxylase (ODC), serum putrescene and spermidine levels were significantly reduced by DFMO, though the decrease in polyamine levels did not directly correlate with the behavioral changes."

• In the new version, the results are even more complicated including statistics at different time points and concentrations, and some of them seem repeated in figure legends, including statistics. The authors may explore other forms of writings the results in a more clear and direct way and take advantage of visual support (figures-tables) to discharge this section. Consider to include it inside the manuscript, better than in supplementary material, since it is something relevant and helpful for the reader.

We appreciate the reviewer efforts to make the paper a better read. We have shortened the figure 2 and 3 legends substantially, and turned S1 Table into Table 1.

• After rewriting the discussion, these sentences "Spermine and spermidine induce a biphasic dose dependent activation/inactivation of NMDA receptors (NMDAR) on cortical neurons and induce pain behavior that can be blocked with NMDAR antagonists (33, 34). It is unknown whether these spinal actions are due to presynaptic or postsynaptic actions." may not be correct. Neither of these works seem to look at the spinal cord. Ref 34 is a study at a peripheral level, and, if fact, shows that NMDAR are not implicated in the nociceptive actions of polyamines (as the authors indicate in fig 4). Perhaps the work by Kolhekar et al. 1994 (Neuroscience 63(4):925-36) could be more adequate to support their affirmation. But anyway the authors must be attentive to this.

We appreciate the reviewers' insights in bringing this important work to our attention and have revised this section.

• Minors:

In page 7/31 is written isoflorane instead of isoflurane

• In page 10/31 is written Prizm instead of Prism

Corrected.

• Reviewer \#2: Authors reply to the observations. Please spell out all the abbreviations the first time they appear

• Ex in the abstract DFMO is spelled out the second time please correct.

Corrected.

10.1371/journal.pone.0236115.r005
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors are aware of the concerns indicated and have taken the actions that they have considered appropriate for their work. I have no further comments.

Reviewer \#2: Authors reply is satisfactory.

Take into account that the resolution of the figures is rather bad, even downloading

them.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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